8-K: Precision BioSciences Q1 2026 Update: Clinical Progress & Financials

Precision BioSciences reported Q1 2026 results, highlighting advancements in its gene editing programs for Hepatitis B and Duchenne Muscular Dystrophy, alongside a cash balance projected to fund operations through 2028.

Summary

• Precision BioSciences reported its first quarter 2026 financial results and provided a business update.
• The company advanced its PBGENE-HBV program in the ELIMINATE-B Phase 1/2a trial and its PBGENE-DMD program, which received FDA IND clearance and Fast Track designation, with the first clinical site activated.
• As of March 31, 2026, the company had $125.8 million in cash, cash equivalents, and restricted cash, which is expected to fund its cash runway through 2028.
• Total revenues for Q1 2026 were $10.8 million, a significant increase from less than $0.1 million in Q1 2025, primarily due to milestone revenue from a license agreement with TG Therapeutics and a legacy collaboration.
• Research and development expenses were $13.1 million, and general and administrative expenses were $6.8 million for Q1 2026.
• The net loss for Q1 2026 was $18.4 million, or $(0.75) per share, compared to a net loss of $20.6 million, or $(2.21) per share, in Q1 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with significant clinical progress and a strong cash position, but offset by continued net losses and the inherent risks of clinical development.

Positives

• Significant increase in total revenues to $10.8 million in Q1 2026 from less than $0.1 million in Q1 2025, driven by milestone payments.
• Cash balance of $125.8 million as of March 31, 2026, is expected to fund operations and key data milestones through 2028.
• PBGENE-DMD program received U.S. FDA IND clearance and Fast Track designation.
• First clinical trial site for the PBGENE-DMD FUNCTION-DMD trial activated and enrolling patients.
• PBGENE-HBV program advanced into new dosing cohorts in the ELIMINATE-B trial.
• Late-breaking poster presentation for PBGENE-HBV accepted at the European Association for the Study of the Liver (EASL) Congress 2026.
• Clinical Trial Application approval received to expand ELIMINATE-B trial into France and Romania.
• Two Notices of Allowance received from the USPTO for patent applications related to the PBGENE-HBV program, expected to issue with a standard expiration date in November 2044.

Negatives

• Net loss of $18.4 million for Q1 2026.
• Total other expense of $9.4 million in Q1 2026, a significant increase from $1.5 million in other income in Q1 2025, primarily due to fair value adjustments.
• Research and development expenses remain substantial at $13.1 million, although slightly decreased from the prior year.

Risks

• The company's ability to become profitable.
• Risks associated with capital requirements and the ability to raise additional capital due to market conditions or market capitalization.
• The progression and success of its programs and product candidates.
• The risk that other genome-editing technologies may provide significant advantages over its ARCUS technology.
• Dependence on its ARCUS technology.
• The initiation, cost, timing, progress, and achievement of milestones and results of research and development activities and preclinical and clinical studies.
• Public perception about genome editing technology and its applications.
• Competition in the genome editing, biopharmaceutical, and biotechnology fields.

Future Outlook

The company expects its current cash and cash equivalents, along with fiscal discipline and its at-the-market facility, to fund its cash runway through 2028, enabling it to achieve key data milestones for its PBGENE-HBV and PBGENE-DMD programs. Precision anticipates sharing further clinical data from the PBGENE-HBV program at hepatitis-focused medical conferences throughout 2026 and expects initial patient screening in France and Romania in the second quarter of 2026.

Management Comments

• "During the first quarter, we continued to execute on our two clinical stage in vivo gene editing programs. We advanced PBGENE-HBV into new cohorts in the ELIMINATE-B trial and drove PBGENE-DMD through Investigational New Drug (IND) approval and activated our first clinical site as we prepare to dose the first patient in the FUNCTION-DMD trial," said Michael Amoroso, Chief Executive Officer of Precision BioSciences.
• "We remain focused on disciplined execution in 2026 as we generate additional clinical data from the ELIMINATE-B trial and enroll more sites and patients in the FUNCTION-DMD trial."
• "We believe our ARCUS platform and targeted development strategy position us to deliver multiple important clinical and operational milestones this year."

Industry Context

StockSavvy.ai notes that Precision BioSciences is operating in the highly competitive and rapidly evolving gene editing therapeutic space. The company's focus on in vivo gene editing for diseases like Hepatitis B and Duchenne Muscular Dystrophy addresses significant unmet medical needs. Advancements in clinical trials and regulatory designations, such as FDA Fast Track, are critical for progress in this sector. The company's financial position, with a projected runway through 2028, is a key factor for sustained development in a capital-intensive industry.

Comparison to Industry Standards

• The revenue increase to $10.8 million in Q1 2026, compared to less than $0.1 million in Q1 2025, is largely attributed to milestone payments from licensing agreements, a common revenue stream for biotech companies in the clinical development phase. This contrasts with companies generating revenue from approved products.
• The net loss of $18.4 million in Q1 2026 is typical for clinical-stage biotechnology companies investing heavily in research and development. Competitors like CRISPR Therapeutics and Editas Medicine also report significant R&D expenses and net losses as they advance their pipelines.
• The cash balance of $125.8 million and a projected runway through 2028 is a critical metric for investors. Companies in this sector often require substantial funding rounds to reach commercialization. Precision BioSciences' runway appears robust compared to some early-stage biotechs that may have shorter funding horizons.

Stakeholder Impact

• Shareholders: Positive impact from clinical advancements and extended cash runway, potentially leading to future value creation. Negative impact from ongoing net losses and stock price volatility.
• Employees: Continued employment and potential for growth as the company advances its programs. Potential impact from operational discipline leading to lower employee-related costs.
• Patients: Potential for new curative treatments for chronic Hepatitis B and Duchenne Muscular Dystrophy through the company's gene editing therapies.
• Creditors: The company's cash position and projected runway suggest a stable financial footing, reducing immediate risk for creditors.

Next Steps

• Share further clinical data from the PBGENE-HBV program at hepatitis-focused medical conferences throughout 2026.
• Initiate site activities and patient screening in France and Romania for the ELIMINATE-B trial in Q2 2026.
• Continue enrollment of patients in the FUNCTION-DMD trial.
• Present preliminary Phase 1 Azer-Cel data in progressive multiple sclerosis in the second half of 2026.
• Commence additional exploratory studies in autoimmune diseases outside of multiple sclerosis.

Key Dates

Recommendation

The company shows promising clinical development in key programs and a solid cash runway, which are positive indicators. However, the significant net loss, the early stage of clinical trials, and the inherent risks in gene editing therapies warrant a cautious 'hold' recommendation until more definitive clinical data and regulatory milestones are achieved.

Keywords

gene editing, Precision BioSciences, PBGENE-HBV, PBGENE-DMD, Hepatitis B, Duchenne Muscular Dystrophy, clinical trials, ARCUS platform